-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 D4z8O9kEr8rgPuOpv1eMVVBWi8TLsOJxCfsimIZswkmG1JkUEjvFfe8mMLcvdt9J
 Ci4QAD+tP2YXEarJVymrCQ==

<SEC-DOCUMENT>0001144204-11-003517.txt : 20110121
<SEC-HEADER>0001144204-11-003517.hdr.sgml : 20110121
<ACCEPTANCE-DATETIME>20110121215000
ACCESSION NUMBER:		0001144204-11-003517
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20110119
FILED AS OF DATE:		20110121
DATE AS OF CHANGE:		20110121

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Pecora Andrew L
		CENTRAL INDEX KEY:			0001510184

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		11542484

	MAIL ADDRESS:	
		STREET 1:		C/O NEOSTEM, INC.
		STREET 2:		420 LEXINGTON AVENUE, SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeoStem, Inc.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		420 LEXINGTON AVENUE
		STREET 2:		SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170
		BUSINESS PHONE:		212-584-4171

	MAIL ADDRESS:	
		STREET 1:		420 LEXINGTON AVENUE
		STREET 2:		SUITE 450
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10170

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNICHE GROUP INC /DE
		DATE OF NAME CHANGE:	19951117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FIDELITY MEDICAL INC
		DATE OF NAME CHANGE:	19951025
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>v208631_ex.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2011-01-19</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000320017</issuerCik>
        <issuerName>NeoStem, Inc.</issuerName>
        <issuerTradingSymbol>NBS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001510184</rptOwnerCik>
            <rptOwnerName>Pecora Andrew L</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O NEOSTEM, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>420 LEXINGTON AVENUE, SUITE 450</rptOwnerStreet2>
            <rptOwnerCity>NEW YORK</rptOwnerCity>
            <rptOwnerState>NY</rptOwnerState>
            <rptOwnerZipCode>10170</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>See Remarks</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Options (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.50</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2011-01-19</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>400000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2021-01-18</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock, par value $0.001 per share</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>400000</value>
                    <footnoteId id="F1"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>400000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">On January 19, 2011, the commencement date of his employment agreement with Progenitor Cell Therapy, LLC (&quot;PCT&quot;), a
 wholly-owned subsidiary of NeoStem, Inc. (the &quot;Company&quot;), the reporting person was granted an option to purchase 400,000
 shares of common stock, par value $0.001 per share, of the Company, pursuant and subject to the terms and conditions of the
 Company's 2009 Equity Compensation Plan.  This option is scheduled to vest as to 100,000 shares on each of January 19, 2012,
 January 19, 2013, January 19, 2014 and January 19, 2015.</footnote>
    </footnotes>

    <remarks>Chief Medical Officer, Progenitor Cell Therapy, LLC, a wholly-owned subsidiary of the Company

The Agreement and Plan of Merger, dated September 23, 2010, among the Company, PCT, and NBS Acquisition Company LLC provides
 that Dr. Pecora will be invited to join the Company's Board of Directors as soon as reasonably practical after the closing
 of the merger.</remarks>

    <ownerSignature>
        <signatureName>Andrew L. Pecora, By: /s/ Catherine M. Vaczy, Esq., Attorney-in-Fact</signatureName>
        <signatureDate>2011-01-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
